PoltregS.A.

Parexel to support PolTREG’s European registration of the world’s first Treg cell therapy for type 1 diabetes

GDAŃSK, Poland, July 31, 2026 – PolTREG S.A. (WSE: PTG), one of the global pioneers in Treg cell therapies, has entered into an agreement with Parexel International (IRL) Limited to support the preparation and submission of its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for PTG-007.

Prof. Piotr Trzonkowski co-authored a prestigious publication in Frontiers in Science with a Nobel Prize winner

The prestigious journal Frontiers in Science has published a review article, “Regulatory T cells: master orchestrators of immune tolerance and tissue homeostasis,” co-authored by Prof. Piotr Trzonkowski, President of the Management Board and Chief Scientific Officer of PolTREG SA. The article was prepared by a group of world leaders in regulatory T cell (Treg) research, including Dr. Frederick J. Ramsdell, winner of the 2025 Nobel Prize in Physiology or Medicine.

Dr. Michael Rosenblum leading University of California (UCSF) immunologist and dermatologist appointed to Immuthera Scientific Advisory Board

June 1, 2026 – Immuthera, the USA subsidiary of PolTREG S.A., an emerging leader in engineered T regulatory (CAR-Treg) cell therapies, today announced the appointment of renowned dermatologist and immunologist Michael Rosenblum, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Rosenblum will help guide the clinical advancement of Immuthera’s first-in-class CD6/CTLA4 CAR-Treg platform as it relates to the development of this therapy in severe dermatological and related autoimmune and…

PolTREG summarizes 2025 – The way to registration in Europe of the world’s first TREG therapy for the treatment of diabetes begins

PolTREG SA, a global leader in the development of therapies using T-regulatory T cells (TREGS), summarized 2025 and presented key milestones for 2026. The company has unique data on a global scale confirming the 12-year effectiveness of TREG therapy in the treatment of diabetes and is preparing to submit an application to the European Medicines Agency (EMA) for central marketing authorization for the therapy in the European Union.

PolTREG has completed the ABB process and will obtain funds to finance key projects with the highest therapeutic and commercial potential

This material is for informational purposes only and does not constitute an offer, nor is it made available, to promote, directly or indirectly, the purchase or acquisition of PolTREG SA securities, or to encourage, directly or indirectly, the purchase or acquisition of such securities. This report does not constitute advertising or promotional material prepared or published by PolTREG SA for the purpose of promoting the shares, their subscription, purchase, or offering, or to encourage…

Life Science Investor Day – PolTREG S.A. participation

On March 11 , representatives of PolTREG S.A. will take part in Life Science Investor Day , organized by Strefa Inwestorów , to discuss the outlook for the biotech sector and the company’s development plans.